Compare PLSE & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | ZYME |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2015 | 2022 |
| Metric | PLSE | ZYME |
|---|---|---|
| Price | $24.74 | $24.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $22.00 | ★ $38.90 |
| AVG Volume (30 Days) | 347.1K | ★ 560.4K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | $840.00 | $183.10 |
| Revenue Next Year | $287.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $12.56 | $11.02 |
| 52 Week High | $27.98 | $29.75 |
| Indicator | PLSE | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 56.18 | 45.51 |
| Support Level | $17.58 | $24.79 |
| Resistance Level | $27.14 | $27.54 |
| Average True Range (ATR) | 1.82 | 1.15 |
| MACD | 0.15 | 0.02 |
| Stochastic Oscillator | 67.22 | 53.19 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.